Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119991 | 1.00 | CNR2 (0.43) | CNR2ACHEPOLBCHRNA7SLC18A3 | |
| SCHEMBL4119987 | 1.00 | CNR2 (0.43) | CNR2ACHEPOLBCHRNA7SLC18A3 | |
| SCHEMBL9498356 | 0.86 | CHRNA7 (0.50) | CHRNA7SLC18A3CHRM4HTR7 | |
| SCHEMBL9748301 | 0.86 | CHRNA7 (0.50) | CHRNA7SLC18A3CHRM4HTR7 | |
| SCHEMBL9748308 | 0.86 | CHRNA7 (0.50) | CHRNA7SLC18A3CHRM4HTR7 | |
| SCHEMBL4128332 | 0.78 | SLC18A3 (0.41) | CHRNA7SLC18A3KDM4EALDH1A1MAPT | |
| SCHEMBL4128329 | 0.78 | SLC18A3 (0.41) | CHRNA7SLC18A3KDM4EALDH1A1MAPT | |
| SCHEMBL4128336 | 0.78 | SLC18A3 (0.41) | CHRNA7SLC18A3KDM4EALDH1A1MAPT | |
| SCHEMBL9492264 | 0.78 | CHRNA7 (0.49) | CHRNA7SLC18A3IDO1TSHR | |
| SCHEMBL4129064 | 0.74 | SLC18A3 (0.40) | CHRNA7SLC18A3ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612061-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090076030-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-20090075982-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-7465733-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20060229318-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075982-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | CNR2 19/4885ACHE 2202/4885POLB 2090/4885 |
| US-20090076030-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | CNR2 19/4885ACHE 2202/4885POLB 2090/4885 |
| US-20060229318-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | CNR2 19/4885ACHE 2202/4885POLB 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.